biote Corp.

Equities

BTMD

US0906831039

Professional Information Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.52 ^USD	-1.08%		-0.36%	+11.74%

Apr. 05	B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating	MT
Apr. 03	CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating	MT

Biote Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 12, 2024 at 04:44 pm EDT

biote Corp. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 45.7 million compared to USD 44.49 million a year ago.

Net income was USD 7.73 million compared to USD 1.62 million a year ago. Basic earnings per share from continuing operations was USD 0.23 compared to USD 0.19 a year ago. Diluted earnings per share from continuing operations was USD 0.18 compared to USD 0.18 a year ago.

Latest news about biote Corp.

B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating	Apr. 05	MT
CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating	Apr. 03	MT
B. Riley Lowers biote's PT to $4 From $6 After Lower-Than-Expected Q4 2023 Results, Says California Regulations Hit Sales Outlook; Maintains Buy Rating	Mar. 26	MT
Biote Corp. completed the acquisition of Asteria Health.	Mar. 13	CI
Roth MKM Adjusts Price Target on Biote to $9 From $8, Maintains Buy Rating	Mar. 13	MT
Transcript : Biote Corp., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Biote Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Biote Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Earnings Flash (BTMD) BIOTE Reports Q4 Revenue $45.7M, vs. Street Est of $45.7M	Mar. 12	MT
Biote Corp. Provides Revenue Guidance for 2024	Mar. 12	CI
B. Riley Securities Starts biote With Buy Rating, $9 Price Target	Feb. 20	MT
Jefferies Starts Biote With Buy Rating, $6.55 Price Target	Feb. 01	MT
Tech Stocks Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	Jan. 26	MT
Biote Board Approves $20 Million Share Repurchase Program	Jan. 26	MT
Biote Corp. announces an Equity Buyback for $20 million worth of its shares.	Jan. 25	CI
Biote Corp. authorizes a Buyback Plan.	Jan. 24	CI
Sector Update: Health Care Stocks Mixed Premarket Thursday	Jan. 18	MT
Roth MKM Trims Price Target on Biote to $7 From $8, Maintains Buy Rating	Jan. 18	MT
Sector Update: Health Care	Jan. 18	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday as Focus Returns to Earnings	Jan. 18	MT
Biote Shares Sink Premarket Following Acquisition Plan of Asteria, Preliminary Q4 Revenue, 2024 Revenue Outlook	Jan. 18	MT
Biote Agrees to Acquire Asteria Health for $8.5 Million; Issues Preliminary Q4 Revenue	Jan. 17	MT
Biote Corp. Provides Revenue Guidance for the Year 2023	Jan. 17	CI
Biote Corp. Provides Revenue Guidance for the Fourth Quarter of 2023, First Half and Full Year of 2024	Jan. 17	CI
Biote Corp. entered into a definitive agreement to acquire Asteria Health for $9 million.	Jan. 16	CI

Chart biote Corp.

Duration

Period

More charts

Company Profile

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Methodâs proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Sector

Professional Information Services

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company